WASHINGTON D.C.- Orexigen Therapeutics Inc. says it is reviving its previously abandoned weight loss drug Contrave, after federal health officials outlined a plan that could bring the drug to market by 2014.
The company said in June that it would not seek U.S. approval for the pill because of "unprecedented" government demands for additional safety studies.
Safety concerns have plagued the effort to develop weight loss drugs for decades.
The company said late Tuesday that the Food and Drug Administration has agreed to a study that could be completed and reviewed by 2014.
The study would involve 10,000 patients and take two years, according to the company. The FDA initially rejected Contrave in February because of concerns about the drug's effects on the heart.
The Associated Press